- Home
- NODK vs GALT Comparison
NODK vs GALT Comparison
Compare NODK & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$6.54
Company Overview
Basic Information| Metric | NODK | GALT |
|---|---|---|
| Founded | 1946 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.8M | 232.3M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | NODK | GALT |
|---|---|---|
| Price | $14.29 | $6.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 13.5K | ★ 465.8K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $297,973,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $126.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.01 | $0.73 |
| 52 Week High | $17.06 | $6.66 |
Technical Indicators
Market Signals| Indicator | NODK | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 70.95 | 61.80 |
| Support Level | $13.31 | $5.10 |
| Resistance Level | $14.08 | $6.32 |
| Average True Range (ATR) | 0.39 | 0.56 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 100.00 | 93.06 |
Price Performance
Historical Comparison NODK
GALT
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.